熔点:138-140°C沸点:777.6±70.0°C(Predicted)密度:1.67储存条件:Keepindarkplace,Inertatmosphere,Storeinfreezer,under-20°C溶解度:Methanol(Slightly)酸度系数(pKa):13.26±0.70(Predicted)形态:Solid颜色:WhitetoOff-White旋光性(opticaChemicalbooklactivity):[α]/D-55to-65°,c=0.2inmethanol稳定性:HygroscopicInChIKey:OEKWJQXRCDYSHL-FNOIDJSQSA-NSMILES:[C@@H]1(O)[C@@H](OCCO)C[C@@H](N2C3C(N=N2)=C(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)N=C(SCCC)N=3)[C@@H]1O
*The following content is generated by AI and is for reference only.
Ticagrelor is a potent, reversible, direct-acting P2Y12 receptor antagonist widely utilized in the management of acute coronary syndromes. With the chemical formula C23H28F3N3O4S and CAS Registry Number 659307-22-3, this medication belongs to the class of cyclopentyl-triazolopyrimidines. Unlike its predecessor clopidogrel, which requires hepatic bioactivation to become effective, ticagrelor acts directly on the platelet surface without metabolic conversion. This pharmacological distinction allows for more rapid onset of action and consistent antiplatelet effects across diverse patient populations, including those with varying genetic polymorphisms affecting cytochrome P450 enzymes.
The primary clinical indication for ticagrelor involves the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), whether managed medically or via percutaneous coronary intervention. It is frequently prescribed as part of dual antiplatelet therapy (DAPT) alongside aspirin. By selectively blocking the binding of adenosine diphosphate (ADP) to the P2Y12 receptor on platelets, ticagrelor inhibits platelet aggregation and prevents the formation of occlusive thrombi within coronary arteries. Its reversibility offers a potential advantage regarding bleeding risk management compared to irreversible agents, allowing platelet function to recover more quickly upon discontinuation.
Beyond its direct mechanism, ticagrelor uniquely increases plasma levels of endogenous adenosine by inhibiting its cellular uptake, which may contribute to additional vasodilatory and cardioprotective benefits. However, this mechanism also necessitates monitoring for specific adverse effects such as dyspnea and bradycardia. The drug is available in various oral tablet strengths, typically 60 mg and 90 mg, facilitating flexible dosing regimens tailored to individual patient needs. Extensive clinical trials have demonstrated its superiority over clopidogrel in reducing rates of death from vascular causes, myocardial infarction, and stroke in high-risk ACS patients. Consequently, ticagrelor remains a cornerstone therapy in modern cardiology, significantly improving outcomes for millions of patients worldwide suffering from coronary artery disease.
(All Rights Reserved)
![6,8-Dioxo-5,7-diazaspiro[3.4]octane-2-carboxylic acid](https://eimg.pharmasources.com/image/product/20250403/02effeb5a7639bc84ff1f3add3c0c64fjpg)
![8,16-Diazadispiro[6.1.6.2]heptadecan-17-one](https://eimg.pharmasources.com/image/product/20250403/ca91cba8b87e53fc879f8d8764873a40jpg)
![8-Oxa-1,3-diazaspiro[4.5]decane-2,4-dione](https://eimg.pharmasources.com/image/product/20250403/60fa7223d5a34f24138486ceea0ffb15jpg)
